Cargando…
PCSK9 and Atherosclerosis - Lipids and Beyond
Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both high and low cholesterol syndromes, a rich body of knowledge has developed, and drugs inhibiting this target have been approved in m...
Autores principales: | Shapiro, Michael D., Fazio, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429160/ https://www.ncbi.nlm.nih.gov/pubmed/28302950 http://dx.doi.org/10.5551/jat.RV17003 |
Ejemplares similares
-
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022) -
An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020) -
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020) -
PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020) -
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015)